Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
28
CODX Quote, Financials, Valuation and Earnings
Last price:
$0.29
Seasonality move
:
-5.34%
Day range:
$0.29 - $0.30
52-week range:
$0.23 - $2.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.61x
P/B ratio:
0.21x
Volume:
177.4K
Avg. volume:
531.9K
1-year change:
-80.84%
Market cap:
$9.9M
Revenue:
$3.9M
EPS (TTM):
-$1.17
Analysts' Opinion
-
Consensus RatingCo-Diagnostics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.50, Co-Diagnostics has an estimated upside of 1764.41% from its current price of $0.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.30.
Fair Value
-
According to the consensus of 2 analysts, Co-Diagnostics has 1764.41% upside to fair value with a price target of $5.50 per share.
CODX vs. S&P 500
-
Over the past 5 trading days, Co-Diagnostics has overperformed the S&P 500 by 1.81% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Co-Diagnostics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Co-Diagnostics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Co-Diagnostics reported revenues of $50.3K.
Earnings Growth
-
Co-Diagnostics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Co-Diagnostics reported earnings per share of -$0.24.
Enterprise value:
-11.5M
EV / Invested capital:
-0.24x
Price / LTM sales:
2.61x
EV / EBIT:
--
EV / Revenue:
-3.30x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.7M
Return On Assets:
-49.96%
Net Income Margin (TTM):
-1025.29%
Return On Equity:
-56.6%
Return On Invested Capital:
-56.6%
Operating Margin:
-17009.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $12.1M | $6.5M | $3.5M | $252.8K | $50.3K | |
| Gross Profit | $9.4M | $2.5M | $2.7M | $18.2K | $28.7K | |
| Operating Income | -$31.4M | -$43M | -$38.4M | -$10.3M | -$8.6M | |
| EBITDA | -$30M | -$41.8M | -$37M | -$9.9M | -$8.3M | |
| Diluted EPS | -$1.01 | -$1.32 | -$1.17 | -$0.31 | -$0.24 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $79.1M | $125.3M | $85.9M | $53.7M | $23.8M | |
| Total Assets | $81.1M | $171.2M | $117M | $86.7M | $55.1M | |
| Current Liabilities | $4.3M | $13M | $3.6M | $5.3M | $5.4M | |
| Total Liabilities | $4.9M | $23.4M | $6.4M | $8.3M | $7.2M | |
| Total Equity | $76.3M | $147.7M | $110.6M | $78.4M | $47.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.2M | -$24.7M | -$29.4M | -$8.5M | -$8.7M | |
| Cash From Investing | -$69.2M | $42.3M | $7.8M | $16.7M | $7.4M | |
| Cash From Financing | -$14.7M | -$881.7K | $458.7K | -- | $354.8K | |
| Free Cash Flow | -$8.4M | -$26.2M | -$29.8M | -$8.9M | -$8.8M | |
CODX
Sector
Market Cap
$9.9M
$33.4M
Price % of 52-Week High
13.23%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
-4.41%
-0.6%
1-Year Price Total Return
-80.84%
-36.6%
Beta (5-Year)
0.574
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.29
200-day SMA
Sell
Level
$0.79
Bollinger Bands (100)
Sell
Level
0.29 - 0.65
Chaikin Money Flow
Sell
Level
-6.6M
20-day SMA
Buy
Level
$0.28
Relative Strength Index (RSI14)
Sell
Level
47.72
ADX Line
Buy
Level
16.46
Williams %R
Neutral
Level
-37.2093
50-day SMA
Sell
Level
$0.32
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-3.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.7247)
Sell
CA Score
(Annual)
Level (-0.9666)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.0656)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Stock Forecast FAQ
In the current month, CODX has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CODX average analyst price target in the past 3 months is $5.50.
-
Where Will Co-Diagnostics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Co-Diagnostics share price will rise to $5.50 per share over the next 12 months.
-
What Do Analysts Say About Co-Diagnostics?
Analysts are divided on their view about Co-Diagnostics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Co-Diagnostics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Co-Diagnostics's Price Target?
The price target for Co-Diagnostics over the next 1-year time period is forecast to be $5.50 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CODX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Co-Diagnostics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CODX?
You can purchase shares of Co-Diagnostics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Co-Diagnostics shares.
-
What Is The Co-Diagnostics Share Price Today?
Co-Diagnostics was last trading at $0.29 per share. This represents the most recent stock quote for Co-Diagnostics. Yesterday, Co-Diagnostics closed at $0.30 per share.
-
How To Buy Co-Diagnostics Stock Online?
In order to purchase Co-Diagnostics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is down 5.6% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is down 2.96% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.69% over the past day.
